Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombin III deficiency.

C H Beresford1

  • 1Department of Pathology, Medical School, University of Otago, Dunedin, New Zealand.

Blood Reviews
|December 1, 1988
PubMed
Summary
This summary is machine-generated.

Reduced antithrombin activity, often due to antithrombin III (AT III) deficiency, can cause severe blood clots. Research has characterized AT III variants and explored recombinant DNA for future treatments and advanced diagnostics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disseminated Beauveria bassiana infection in a patient with acute lymphoblastic leukemia.

Journal of clinical microbiology·2004
Same author

Iron deficiency and anaemia in a longitudinal study of New Zealanders at ages 11 and 21 years.

The New Zealand medical journal·1998
Same author

A new beta chain variant, Hb Tyne [beta 5(A2)Pro-->Ser].

Hemoglobin·1994
Same author

Polycythaemia associated with homozygosity for the abnormal haemoglobin Sherwood Forest (beta 104 (G6)Arg-->Thr).

British journal of haematology·1994
Same author

A recurrent deletion in the antithrombin gene, AT106-108(-6 bp), identified by DNA heteroduplex detection.

Genomics·1993
Same author

Iron deficiency.

The New Zealand medical journal·1992
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Area of Science:

  • Biochemistry
  • Genetics
  • Hematology

Background:

  • Moderate reduction in plasma antithrombin activity is a rare but significant cause of severe thromboembolic disease.
  • Antithrombin III (AT III) has been extensively characterized, with over 30 autosomally dominant inheritable variants identified.

Purpose of the Study:

  • To elucidate the molecular basis and inheritance of familial antithrombin deficiencies.
  • To explore the potential of recombinant DNA technology for producing functional AT III and advancing diagnostic methods.

Main Methods:

  • Gene sequencing of normal human antithrombin III.
  • Analysis of familial deficiency inheritance patterns.
  • Application of recombinant DNA methods for AT III production.
  • Utilizing restriction fragment length polymorphisms and synthetic oligonucleotide probes for diagnostics.

Related Experiment Videos

Main Results:

  • Detailed characterization of antithrombin III and its variants.
  • Insights into the reaction mechanisms between antithrombin, thrombin, and heparin.
  • Successful production of functionally active recombinant AT III.
  • Development of advanced diagnostic techniques for AT III deficiencies.

Conclusions:

  • Understanding antithrombin III structure and function is crucial for managing thromboembolic disorders.
  • Recombinant AT III shows promise as a future therapeutic agent.
  • Novel diagnostic tools offer improved accuracy and antenatal screening capabilities for hereditary AT III deficiencies.